Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells

Molecular Pharmacology

Volumn 49, Issue 3, 1996, Pages 532-539

  Mankhetkorn, Samlee ^a   Dubru, Franck ^a   Hesschenbrouck, Joelle ^a   Fiallo, Marina ^a   Garnier Suillerot, Arlette ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

[No Author keywords available]

Indexed keywords

8 FLUOROIDARUBICIN; DAUNORUBICIN; DOXORUBICIN; GLYCOPROTEIN P; IDARUBICIN; IDARUBICIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL LEVEL; CELL MEMBRANE TRANSPORT; CELL STRAIN K 562; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG UPTAKE; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; CELL DIVISION; CELL MEMBRANE PERMEABILITY; CELL NUCLEUS; DAUNORUBICIN; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; HUMANS; IDARUBICIN; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MICROBIAL SENSITIVITY TESTS; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED;

EID: 0029922333     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Bradley, G., P. F. Juranka, and V. Ling. Mechanism of multidrug resistance. Biochim. Biophys. Acta 948:87-128 (1988).
2. Gottesman, M. M., and I. Pastan. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:385-427 (1993).
3. Dano, K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim. Biophys. Acta 323:466-483 (1973).
4. Juliano, R. L., and V. Ling. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta. 455:152-162 (1976).
5. Skovsgaard, T. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumors cells. Cancer Res. 38:1785-1791 (1978).
6. Beck, W. T., T. J. Mullen, and L. R. Lanzen. Altered surface membrane glycoprotein in Vinca alkaloid-resistant human leukemia lymphoma. Cancer Res. 39:2070-2076 (1979).
7. Riordan, J. R., and V. Ling. Genetic and biochemical characterization of multidrug resistance. Pharmacol. Ther. 28:51-75 (1985).
8. Ueda, K., C. Cardarelli, M. M. Gottesman, and I. Pastan. Expression of a full-length cDNA for the human 'MDR1' (P-glycoprotein) gene confers multidrug resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. USA 84:3004-3008 (1987).
9. Chen, C. J., J. E. Chin, K. Ueda, D. Clark, I. Pastan, and M. M. I. Roninson. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant cells. Cell 47:381-389 (1986).
10. Gros, P., J. Croop, and D. E. Housman. Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 47:371-380 (1986).
11. Tsuruo, T., S. Tsukagoshi, and Y. Sakurai. Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell line by calcium antagonists and calmodulin inhibitors. Cancer Res. 43:2267-2272 (1983).
12. Beck, W. T., M. C. Cirtain, A. T. Look, and R. A. Ashmun. Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil. Cancer Res. 46:778-784 (1986).
13. Inaba, M., and E. Maruyama. Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs with a special emphasis on quinacreine. Cancer Res. 48:2064-2067 (1988).
14. Twentyman, P. R., N. E. Fox, K. A. Wright, P. Workman, M. J. Broadhurst, J. A. Martin, and J. A. Bleehen. The in vitro effects and cross-resistance patterns of some novel anthracyclines. Br. J. Cancer 53:585-594 (1986).
15. Coley, H. M., P. R. Twentyman, and P. Workman. Further examination of 9-alkyl- and sugar-modified anthracyclines in the circumvention of multidrug resistance. Anti-Cancer Drug Des. 7:471-481 (1992).
16. Priebe, W., and R. Prerez-Soler. Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach. Pharmacol. Ther. 60:215-234 (1993).
17. Priebe, W., N. T. Van, T. G. Burke, and R. Perezsoler. Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity. Anti-Cancer Drug Des. 4:37-48 (1993).
18. Pearce, H. L., A. R. Safa, N. J. Winter, M. C Cirtain, and W. T. Beck. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc. Natl. Acad. Sci. USA 86:5128-5132 (1989).
19. Saeki, T., K. Ueda, Y. Tanigawara, R. Hori, and T. Komano. Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268: 6077-6080 (1993).
20. Lozzio, C B., and B. B. Lozzio Human chronic myelogeneous leukemia cell line positive Philadelphia chromosome. Blood 45:321-334 (1975).
21. Tsuruo, T., H. Iida, H. Kawataba, T. Oh-Hara, H. Hamada, and T. Utakoji. Characteristics of resistance to adriamycin in human myelogeneous leukemia K562 resistant to adriamycin and in isolated clones. Jpn. J. Cancer Res. 77:682-687 (1986).
22. Maniatis, T., E. Fristch, and J. Sambrook. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1982).
23. Ferrandis, E., J. Da Silva, J. Riou, and J. Benard. Coactivation of the MDR1 and MYCN genes in human neuroblastoma cells during the metastatic process in the nude mouse. Cancer Res. 54:2256-2261 (1994).
24. Golstein, L. J., A. T. Fojo, W. Crist, A. Green, G. Brodeur, I. Pastan, and M. M. Gottesman. Expression of the multidrug resistance, MDR1, gene in neuroblastomas. J. Clin. Oncol. 8:128-136 (1990).
25. Guidi, A., F. Canfarini, A. Giolitti, F. Pasqui, V. Pestellini, and F. Arcamone. Synthesis of new antitumor anthracyclines: derivatives bearing a fluorine substitution at position 8 or 10. Pure Appl. Chem. 66:2319-2322 (1994).
26. Tarasiuk, J., F. Frézard, A Garnier-Suillerot, and L. Gattegno. Anthracycline incorporation in human lymphocytes: kinetics of uptake and nuclear concentration. Biochim. Biophys. Acta 1013:109-117 (1989).
27. Frézard, F., and A. Garnier-Suillerot. Comparison of the membrane transport of anthracycline derivatives in drug-resistant and drug-sensitive K562 cells. Eur. J. Biochem 196:483-491 (1991).
28. Frézard, F., and A. Garnier-Suillerot. Determination of the osmotic active drug concentration in the cytoplasm of anthracycline-resistant and -sensitive K562 cells. Biochim. Biophys. Acta 1091:29-55 (1991).
29. Pereira, E., M. N. Borrel, M. Fiallo, and A. Garnier-Suillerot. Non-competitive inhibition of P-glycoprotein-associated efflux of THP-adriamycin by verapamil in living K562 cells. Biochim. Biophys. Acta 1225:209-216 (1994).
30. Borrel, M. N., M. Fiallo, W. Priebe, and A. Garnier-Suillerot. P-glycoprotein-mediated efflux of hydroxyrubicin, a neutral anthracycline derivative, in resistant K562 cells. FEBS Lett. 356:287-290 (1994).
31. Frézard, F., and A. Garnier-Suillerot. Comparison of the binding of anthracycline derivatives to purified DNA and to cell nuclei. Biochim. Biophys. Acta 1036:121-127 (1990).
32. Slapak, C. A., J.-M Lecerf, J. C. Daniel, and S. B. Levy. Energy-dependent accumulation of daunorubicin into subcellular compartments of human leukemia cells and cytoplasts. J. Biol. Chem. 267:10638-10644 (1992).
33. Hill, T. Cooperative Theory in Biochemistry. Springer-Verlag, Berlin, 63-67 (1985).
34. Spoelstra, E., H. Westerhoff, H. Dekker, and J. Lankelma. Kinetics of daunonibicin transport by P-glycoprotein of intact cancer cells. Eur. J. Biochem. 207:567-579 (1992).
35. Guiral, G., O. Viratelle, H. Westerhoff, and J. Lankelma. Cooperative P-glycoprotein-mediated daunorubicin transport into DNA-loaded plasma membrane vesicles. FEBS Lett. 346:141-145 (1994).
36. Berman, E., and M. McBride. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 79:3267-3273 (1992).
37. Facchetti, I., M. Grandi, P. Cicchi, C. Geroni, S. Penco, and A. Vigevani. Influence of lipophilicity on cytotoxicity of anthracyclines in LoVo and LoVo/Dx human cell lines. Anti-Cancer Drug Des. 6:385-397 (1991).
38. Schott, B. and, J. Robert. Comparative cytotoxicity and drug incorporation of eight anthracyclines in a model of doxonibicin-sensitive and -resistant rat gliostoma cells. Biochem. Pharmacol. 38:167-172 (1989).
39. Friche, E., P. Buhl Jensen, H. Roed, T. Skovsgaard, and N.I. Nissen. In vitro circumvention of anthracycline-resistance in Ehrlich ascites tumor by anthracydine analogues. Biochem. Pharmacol. 39:1721-1728 (1990).
40. Tang-Wai, D. F., A. Brossi, L. D. Arnold, and P. Gros. The nitrogen of the acetamido group of colchicine modulates P-glycoprotein-mediated multidrug resistance. Biochemistry 32:6470-6776 (1993).
41. Skovsgaard, T. Circumvention of resistance to daunorubicin and N-acetyl-daunonobicin in Ehrlich ascites tumor. Cancer Res. 40:1077-1083 (1980).
42. Gros, P., F. Talbot, T.-W. David, E. Bibi, and H. R. Kabck. Lipophilic cations: a group of model substrates for the multidrug-resistance transporter. Biochemistry 31:1992-1998 (1992).